The anti-inflammatory activity of cannabis extracts on colon cells came from THCA (the raw, unheated form of THC), not from CBD, and worked through the GPR55 receptor rather than classical cannabinoid receptors.
Read this if you have IBD and want to understand which cannabis compound may actually reduce gut inflammation.
THCA, not CBD, was the primary anti-inflammatory compound in cannabis for colon inflammation
What the researchers found
This study systematically characterized which components of cannabis extracts produce anti-inflammatory effects in colon models relevant to inflammatory bowel disease.
The anti-inflammatory activity was traced to a specific fraction containing delta-9-tetrahydrocannabinolic acid (THCA), the raw precursor to THC found in unheated cannabis. THCA reduced interleukin-8 (a key inflammatory marker) in both colon cell lines and in tissue biopsies from IBD patients.
The effects were mediated at least partially through the GPR55 receptor, not the classical CB1 or CB2 cannabinoid receptors. A GPR55 antagonist significantly reduced the anti-inflammatory activity, while a CB2 antagonist affected cell proliferation rather than inflammation.
CBD showed a different pattern: it had dose-dependent cytotoxic (cell-killing) activity, but its anti-inflammatory activity occurred only at low concentrations and in a bell-shaped manner (effective at low doses, ineffective at higher ones).
The authors concluded that for non-psychoactive IBD treatment, THCA should be preferred over CBD.
Why it matters
This study redirects the focus of cannabis-based IBD therapy from CBD (which showed limited anti-inflammatory activity) to THCA (which was highly effective). Since THCA is non-psychoactive (it has not been heated/decarboxylated into THC), it could provide anti-inflammatory benefits without the high.
The numbers in context
THCA in fraction 7 was the primary anti-inflammatory component. GPR55 antagonist significantly reduced anti-inflammatory activity. CBD showed bell-shaped anti-inflammatory response (effective only at low concentrations). Results confirmed in IBD patient tissue biopsies.
How the study worked
Cannabis flowers were extracted with ethanol and fractionated. Anti-inflammatory activity was tested on three epithelial cell lines and colon tissue biopsies from IBD patients. Chemical analysis used HPLC, mass spectrometry, and NMR. Gene expression of COX2 and MMP9 was measured by qRT-PCR. Receptor involvement was tested using specific antagonists.
What this study cannot tell us
In vitro and ex vivo study; clinical effects in patients have not been tested. The extract fractionation process may not reflect whole-plant cannabis effects. THCA stability (it converts to THC with heat) creates formulation challenges for clinical use.
How to read the evidence
In vitro and ex vivo study with systematic fractionation and receptor characterization. Preliminary because clinical effects have not been tested.
When this study was published
Published in 2017.
The bigger picture
This finding challenges the popular focus on CBD for inflammatory conditions and highlights THCA as a potentially superior anti-inflammatory cannabinoid for gut disease. The involvement of GPR55 rather than CB1/CB2 receptors opens new pharmacological targets.
Questions still open
- Could THCA-rich preparations be developed as non-psychoactive IBD treatments? Would oral THCA survive stomach acid and reach the colon intact? How does GPR55 signaling in the gut mediate anti-inflammatory effects?
Common questions
Is CBD or THC better for gut inflammation?
What is THCA?
Read the original research
Anti-Inflammatory Activity in Colon Models Is Derived from Δ9-Tetrahydrocannabinolic Acid That Interacts with Additional Compounds in Cannabis Extracts.
Cannabis and cannabinoid research, 2(1), 167-182
Citation
Nallathambi, Rameshprabu; Mazuz, Moran; Ion, Aurel; Selvaraj, Gopinath; Weininger, Smadar; Fridlender, Marcelo; Nasser, Ahmad; Sagee, Oded; Kumari, Puja; Nemichenizer, Diana; Mendelovitz, Maayan; Firstein, Nave; Hanin, Orly; Konikoff, Fred; Kapulnik, Yoram; Naftali, Timna; Koltai, Hinanit. (2017). Anti-Inflammatory Activity in Colon Models Is Derived from Δ9-Tetrahydrocannabinolic Acid That Interacts with Additional Compounds in Cannabis Extracts.. Cannabis and cannabinoid research, 2(1), 167-182. https://doi.org/10.1089/can.2017.0027
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk